Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol in pediatric chronic kidney disease with secondary hyperparathyroidism
2010-019439-37Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) comparing Paricalcitol with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving sustained iPTH reduction. Started Jul 2010; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2010-019439-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019439-37.